Medicine Information

g-Montelukast

Name: g-Montelukast
Brand: g-Montelukast
Rating: 4.5 (117 reviews)

Tablet5 mgLeukotriene Receptor AntagonistsATC: R03DC03

Generic Name

Montelukast 5 mg tablet

Manufacturer

General Pharma Ltd.

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
g montelukast 5 mg tablet	৳ 6.00	৳ 60.00

Description

Overview of the medicine

Montelukast is a leukotriene receptor antagonist used for the prevention and chronic treatment of asthma and for the relief of symptoms of seasonal and perennial allergic rhinitis. This 5 mg tablet is typically prescribed for pediatric patients aged 6 to 14 years.

Uses & Indications

Prophylaxis and chronic treatment of asthma, including prevention of day- and nighttime asthma symptoms.

Prevention of exercise-induced bronchoconstriction (EIB).

Relief of daytime and nighttime symptoms of seasonal allergic rhinitis in patients aged 6 years and older.

Relief of daytime and nighttime symptoms of perennial allergic rhinitis in patients aged 6 years and older.

Dosage

Renal_impairment

No dosage adjustment is necessary.

Children_6_to_14_years

One 5 mg tablet taken once daily in the evening. For asthma, it should be taken in the evening. For allergic rhinitis, the time of administration may be individualized to suit patient needs.

Adults_and_adolescents_15_years_and_older

One 10 mg tablet taken once daily in the evening (5 mg tablet is not typically indicated for this age group for routine use).

How to Take

Administer orally once daily in the evening. The tablet may be taken with or without food. For allergic rhinitis, the time of administration may be individualized.

Mechanism of Action

Montelukast selectively antagonizes the CysLT1 receptor, blocking the action of leukotriene D4 (LTD4), a potent inflammatory mediator. This action reduces bronchoconstriction and inflammatory responses in the airways, improving asthma control and alleviating allergic rhinitis symptoms.

Pharmacokinetics

Onset

Within 1 day for asthma and allergic rhinitis symptoms.

Excretion

Primarily excreted in the feces (approximately 86%) via bile; less than 0.2% is excreted in urine.

Half life

Approximately 2.7 to 5.5 hours.

Absorption

Rapidly absorbed after oral administration; mean oral bioavailability is approximately 64%. Peak plasma concentrations are reached in about 2-4 hours.

Metabolism

Extensively metabolized in the liver by cytochrome P450 enzymes, primarily CYP3A4, 2C8, and 2C9.

Side Effects

Contraindications

Known hypersensitivity to montelukast or any component of the formulation.

Drug Interactions

Rifampin

Can induce montelukast metabolism, potentially reducing its efficacy. Clinical monitoring is recommended.

Phenobarbital

May decrease the area under the curve (AUC) of montelukast by approximately 40%, requiring clinical monitoring.

Storage

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

Overdose

In post-marketing experience and clinical studies, there have been reports of acute overdose. The most frequently observed adverse events were abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity. Treatment is symptomatic and supportive.

Pregnancy & Lactation

Pregnancy Category B. Studies in animals have not shown harm to the fetus, but there are no adequate and well-controlled studies in pregnant women. Use only if clearly needed. Montelukast is excreted in breast milk; caution is advised when administered to a nursing woman.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

10 tablets per blister, 3 blisters per box (30 tablets)15 tablets per blister, 2 blisters per box (30 tablets)

Shelf Life

36 months (3 years)

Availability

Pharmacies, hospitals, clinics

Approval Status

Approved

Patent Status

Off-patent

WHO Essential Medicine

Yes

Clinical Trials

Montelukast has undergone extensive clinical trials demonstrating its efficacy and safety in the treatment of asthma and allergic rhinitis across various age groups. Studies have supported its role in improving lung function, reducing symptom frequency, and decreasing the need for rescue medication.

Lab Monitoring

No routine laboratory monitoring is required. Clinical monitoring of asthma symptoms and potential adverse effects is recommended.

Doctor Notes

Emphasize that Montelukast should be taken daily for chronic control, not for acute relief.
Educate patients/parents on monitoring for neuropsychiatric symptoms and reporting them immediately.
Review proper use of concomitant asthma medications, including rescue inhalers.

Patient Guidelines

Take this medicine once daily, preferably in the evening, even when feeling well, to maintain asthma control.
This medicine is not for sudden asthma attacks; use a fast-acting inhaler for rescue.
Inform your doctor if you experience any mood changes, agitation, depression, or suicidal thoughts.
Continue taking other asthma medications unless directed otherwise by your doctor.

Missed Dose Advice

If a dose is missed, take the next dose at the regular time. Do not take an extra dose to make up for a missed dose. Continue with the regular dosing schedule.

Driving Precautions

May cause dizziness or somnolence in some individuals. Patients should be aware of how they react to montelukast before driving or operating machinery.